Colitis Clinical Trial
Official title:
Intestinal Biomarker Analysis After ECP for ICI Colitis
It was previously shown that ICI-colitis can be treated with extracorporeal photophoresis. Therefore this retrospective analysis is launched to study the chnages of immune cells in the peripheral blood and intestinal tract in an ICI colitis patient cohort. The analysis will include the evaluation of intestinal and peripheral blood biomarkers in patients with ICI colitis receiving ECP as a treatment.
It was previously shown that ICI-colitis can be treated with extracorporeal photophoresis. Therefore this retrospective analysis is launched to study the changes of immune cells in the peripheral blood and intestinal tract in an ICI colitis patient cohort. The analysis will include the evaluation of intestinal and peripheral blood biomarkers in patients with ICI colitis receiving ECP as a treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00272818 -
Study to Identify Non-Invasive Markers of Gastrointestinal Allergy
|
||
| Completed |
NCT01369355 -
A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)
|
Phase 3 | |
| Completed |
NCT02709213 -
Determination of the Aetiologies of Acute Colitis and Early Identification of Patients Requiring Diagnostic Colonoscopy
|
||
| Completed |
NCT00533078 -
Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies
|
Phase 2 | |
| Terminated |
NCT00184171 -
Treatment of Microscopic Colitis
|
N/A | |
| Recruiting |
NCT05333978 -
Optoacoustic Detection of Inflammation Using MSOT Device
|
N/A | |
| Recruiting |
NCT02768038 -
Intestinal Microbiome and Chronic Inflammatory Bowel Disease
|
||
| Recruiting |
NCT04272307 -
MIcroorganisms as Triggers in Acute Severe Ulcerative Colitis and Their Influence on Medical Therapy Efficacy: a Multi-omics Pilot Approach.
|
||
| Completed |
NCT05514561 -
FIT and Fecal Calprotectin in Patients With Chronic Lower GI Symptoms
|
||
| Completed |
NCT00072943 -
A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease
|
Phase 2 | |
| Recruiting |
NCT02687724 -
Golimumab (GLM) Dose Optimisation to Adequate Levels to Achieve Response in Colitis
|
Phase 4 | |
| Completed |
NCT02647866 -
Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
|
Phase 2 | |
| Completed |
NCT01326013 -
A Two-Arm, Multi-Centre Clinical Evaluation of the xTAG Gastrointestinal Pathogen Panel
|
Phase 2 | |
| Not yet recruiting |
NCT05726396 -
A Pilot Study Testing the Safety and Feasibility of Restorative Microbiota Therapy (RMT) in Patients With Refractory Immune-checkpoint Inhibitor-related Colitis
|
Phase 2 | |
| Completed |
NCT05414552 -
ECP for Immune-related Adverse Events After Checkpoint Inhibitor Treatment
|
||
| Recruiting |
NCT04407247 -
Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma
|
Phase 1/Phase 2 | |
| Completed |
NCT01369342 -
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
|
Phase 3 | |
| Completed |
NCT01369329 -
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
|
Phase 3 | |
| Terminated |
NCT00936585 -
NIH Substudy of AIN457 (Anti-IL-17 Monoclonal Antibody) for Treatment of Moderate to Severe Crohn's Disease
|
N/A | |
| Recruiting |
NCT06206707 -
FMT in Checkpoint Inhibitor-mediated Diarrhea and Colitis
|
N/A |